Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01796041 · ClinicalTrials.gov registry record · Early Phase 1
Intraoperative Imaging of Breast Cancer With Indocyanine Green
A Early Phase 1 study of Invasive Ductal Carcinoma and Ductal Carcinoma, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01796041 is a Early Phase 1 study of Invasive Ductal Carcinoma and Ductal Carcinoma that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01796041, a Early Phase 1 study of Invasive Ductal Carcinoma and Ductal Carcinoma, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
According to the World Health Organization, breast cancer is the most common cancer in women, and is responsible for 686,000 new cases every year. The WHO also posit that nearly 420,000 women perished from the disease in 2002. Surgery remains the best option for patients presenting with operable Stage I, II or III cancers. Breast conservation surgery has been shown to be as efficacious as mastectomy. About 60-70% of these women with operable breast cancer are breast conservation candidates. However, the need to achieve negative tumor margins often requires a second operation (re-excision) in up to 70% of the women having lumpectomy surgery. Currently, tumor margins assessment in the operating room is often assessed grossly by palpation. The ability to evaluate tumor margin using our proposed intraoperative imaging technique may provide the surgeon with an alternative, and hopefully, more sensitive method to assess tumor margins which may decrease re-excision and the morbidity associated with additional surgery, and, perhaps, lower the risk of local regional recurrence.
Conditions Studied
Interventions
- DRUG Indocyanine Green
Study Locations (1)
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-07 |
| Est. Completion | 2016-11-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01796041
The ClinicalTrials.gov registry entry for NCT01796041 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Invasive Ductal Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Indocyanine Green is the first listed.
NCT01796041 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01796041 about?
NCT01796041 is a clinical study titled "Intraoperative Imaging of Breast Cancer With Indocyanine Green". According to the World Health Organization, breast cancer is the most common cancer in women, and is responsible for 686,000 new cases every year. The WHO also posit that nearly 420,000 women perished from the disease in 2002. Surgery remains the best option for patients presenting with operable Sta...
What is the current status of trial NCT01796041?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2011-07. Estimated completion is 2016-11-09.
What conditions does trial NCT01796041 study?
This clinical trial studies the following conditions: Invasive Ductal Carcinoma, Ductal Carcinoma, Invasive Lobular Carcinoma.
What interventions are being tested in trial NCT01796041?
The interventions under investigation include: Indocyanine Green (DRUG).
Who is sponsoring clinical trial NCT01796041?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01796041 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Ductal Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.